Janssen’s Spravato Beats Antipsychotic In Depression Trial Designed To Increase Uptake
Executive Summary
The controversial nasal spray has improved remission rates over an atypical antipsychotic in patients with a challenging form of depression, in Phase III data which could help boost its uninspiring market performance to date.
You may also be interested in...
J&J Hedges On 2025 Pharma Revenue Outlook
The company admitted it may not meet a goal set in 2021 to reach a $60bn pharmaceutical revenue target in 2025.
Janssen Secures Only Partial Win In Appeal Against English Funding Snub For Spravato
Of the nine specific appeal points raised against NICE’s rejection of the company’s antidepressant nasal spray, Spravato, just one was upheld.
New ‘Emergency’ Market Beckons For Spravato Depression Spray
The therapeutic indication of Spravato is set to be expanded in the EU after receiving the thumbs up from the European Medicines Agency. The nasal spray has been shown to reduce depressive symptoms in just four hours and would fill a key unmet need, says the drug’s developer, Janssen.